9,951 Shares in Neurocrine Biosciences, Inc. $NBIX Purchased by National Pension Service

National Pension Service purchased a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the third quarter, HoldingsChannel reports. The firm purchased 9,951 shares of the company’s stock, valued at approximately $1,397,000.

A number of other hedge funds also recently made changes to their positions in the business. Vanguard Personalized Indexing Management LLC raised its stake in Neurocrine Biosciences by 0.7% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 11,112 shares of the company’s stock valued at $1,560,000 after acquiring an additional 77 shares during the period. Diametric Capital LP boosted its position in Neurocrine Biosciences by 2.6% during the second quarter. Diametric Capital LP now owns 3,244 shares of the company’s stock worth $408,000 after purchasing an additional 81 shares during the period. Great Lakes Advisors LLC increased its holdings in shares of Neurocrine Biosciences by 2.4% in the third quarter. Great Lakes Advisors LLC now owns 3,605 shares of the company’s stock valued at $506,000 after purchasing an additional 84 shares during the last quarter. IFP Advisors Inc raised its position in shares of Neurocrine Biosciences by 4.2% in the second quarter. IFP Advisors Inc now owns 2,172 shares of the company’s stock valued at $273,000 after purchasing an additional 88 shares during the period. Finally, Linden Thomas Advisory Services LLC lifted its stake in shares of Neurocrine Biosciences by 1.5% during the 2nd quarter. Linden Thomas Advisory Services LLC now owns 6,699 shares of the company’s stock worth $842,000 after buying an additional 96 shares during the last quarter. 92.59% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

NBIX has been the topic of a number of research reports. Wall Street Zen lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Weiss Ratings restated a “hold (c+)” rating on shares of Neurocrine Biosciences in a report on Thursday, January 22nd. Mizuho upped their target price on Neurocrine Biosciences from $146.00 to $175.00 and gave the company a “neutral” rating in a research report on Friday, December 12th. Piper Sandler lifted their price target on Neurocrine Biosciences from $175.00 to $179.00 and gave the stock an “overweight” rating in a report on Wednesday, October 29th. Finally, Needham & Company LLC boosted their price target on Neurocrine Biosciences from $170.00 to $184.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Seventeen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $174.25.

Neurocrine Biosciences Price Performance

Shares of NASDAQ:NBIX opened at $138.98 on Wednesday. The company has a market capitalization of $13.86 billion, a P/E ratio of 33.25, a P/E/G ratio of 0.64 and a beta of 0.31. Neurocrine Biosciences, Inc. has a 1 year low of $84.23 and a 1 year high of $160.18. The business’s 50 day simple moving average is $142.97 and its 200 day simple moving average is $140.38.

Insider Buying and Selling

In related news, insider Darin Lippoldt sold 4,376 shares of the company’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $159.65, for a total transaction of $698,628.40. Following the completion of the sale, the insider owned 43,405 shares of the company’s stock, valued at $6,929,608.25. This represents a 9.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director George J. Morrow sold 15,000 shares of the stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $143.37, for a total transaction of $2,150,550.00. Following the sale, the director owned 7,068 shares in the company, valued at $1,013,339.16. The trade was a 67.97% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 61,966 shares of company stock valued at $8,625,166. 4.30% of the stock is owned by insiders.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.